Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer.

Wu SY, Boreta L, Shinohara K, Nguyen H, Gottschalk AR, Hsu IC, Roach M 3rd, Westphalen AC, Feng FY, Carroll PR, Chang AJ, Hope TA.

Urology. 2019 Mar;125:154-162. doi: 10.1016/j.urology.2018.09.038. Epub 2018 Dec 21.

PMID:
30580002
2.

Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy.

Chapman CH, Braunstein SE, Pouliot J, Noworolski SM, Weinberg V, Cunha A, Kurhanewicz J, Gottschalk AR, Roach MI, Hsu IC.

J Contemp Brachytherapy. 2018 Jun;10(3):193-201. doi: 10.5114/jcb.2018.76881. Epub 2018 Jun 29.

3.

Influence of respiratory motion management technique on radiation pneumonitis risk with robotic stereotactic body radiation therapy.

Chapman CH, McGuinness C, Gottschalk AR, Yom SS, Garsa AA, Anwar M, Braunstein SE, Sudhyadhom A, Keall P, Descovich M.

J Appl Clin Med Phys. 2018 Jul;19(4):48-57. doi: 10.1002/acm2.12338. Epub 2018 Apr 26.

4.

ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II.

Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ.

Adv Radiat Oncol. 2017 Mar 20;2(3):437-454. doi: 10.1016/j.adro.2017.03.003. eCollection 2017 Jul-Sep. Review.

5.

ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II.

Expert Panel on Radiation Oncology-Prostate:, Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ.

Adv Radiat Oncol. 2016 Oct 20;2(1):62-84. doi: 10.1016/j.adro.2016.10.002. eCollection 2017 Jan-Mar. Review. No abstract available.

6.

Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer.

Zhang L, Johnson J, Gottschalk AR, Chang AJ, Hsu IC, Roach M 3rd, Seymour ZA.

Pract Radiat Oncol. 2017 Mar - Apr;7(2):e109-e116. doi: 10.1016/j.prro.2016.07.004. Epub 2016 Jul 17.

PMID:
28274401
7.

Respiration-Induced Intraorgan Deformation of the Liver.

Paulsson AK, Yom SS, Anwar M, Pinnaduwage D, Sudhyadhom A, Gottschalk AR, Chang AJ, Descovich M.

Technol Cancer Res Treat. 2017 Jan 1:1533034616687193. doi: 10.1177/1533034616687193. [Epub ahead of print]

8.

ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer.

McLaughlin PW, Liss AL, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, Movsas B, Prestidge BR, Showalter TN, Taira AV, Vapiwala N, Davis BJ; Expert Panel on Radiation OncologyProstate.

Am J Clin Oncol. 2017 Feb;40(1):1-10. doi: 10.1097/COC.0000000000000354.

PMID:
28059930
9.

ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer.

Davis BJ, Taira AV, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Showalter TN, Vapiwala N.

Brachytherapy. 2017 Mar - Apr;16(2):266-276. doi: 10.1016/j.brachy.2016.10.002. Epub 2016 Dec 7.

PMID:
27964905
10.

Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity.

Woodard GA, Crockard JC, Clary-Macy C, Zoon-Besselink CT, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM.

J Surg Oncol. 2016 Dec;114(7):838-847. doi: 10.1002/jso.24409. Epub 2016 Aug 28.

PMID:
27569043
11.

Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes.

Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M 3rd, Carroll PR.

PLoS One. 2016 Oct 6;11(10):e0164558. doi: 10.1371/journal.pone.0164558. eCollection 2016.

12.

An Evaluation of Robotic and Conventional IMRT for Prostate Cancer: Potential for Dose Escalation.

Pinnaduwage DS, Descovich M, Lometti MW, Varad B, Roach M 3rd, Gottschalk AR.

Technol Cancer Res Treat. 2017 Jun;16(3):267-275. doi: 10.1177/1533034616639729. Epub 2016 Mar 31.

13.

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.

Anwar M, Weinberg V, Seymour Z, Hsu IJ, Roach M 3rd, Gottschalk AR.

Radiat Oncol. 2016 Jan 21;11:8. doi: 10.1186/s13014-016-0585-y.

14.

Investigating the clinical advantages of a robotic linac equipped with a multileaf collimator in the treatment of brain and prostate cancer patients.

McGuinness CM, Gottschalk AR, Lessard E, Nakamura JL, Pinnaduwage D, Pouliot J, Sims C, Descovich M.

J Appl Clin Med Phys. 2015 Sep 8;16(5):284–295. doi: 10.1120/jacmp.v16i5.5502.

15.

Intraoperative Radiotherapy in the Management of Locally Recurrent Extremity Soft Tissue Sarcoma.

Tinkle CL, Weinberg V, Braunstein SE, Wustrack R, Horvai A, Jahan T, O'Donnell RJ, Gottschalk AR.

Sarcoma. 2015;2015:913565. doi: 10.1155/2015/913565. Epub 2015 Aug 9.

16.

Patient- and treatment-specific predictors of genitourinary function after high-dose-rate monotherapy for favorable prostate cancer.

Raleigh DR, Chang AJ, Tomlin B, Cunha JA, Braunstein SE, Shinohara K, Gottschalk AR, Roach M 3rd, Hsu IC.

Brachytherapy. 2015 Nov-Dec;14(6):795-800. doi: 10.1016/j.brachy.2015.06.004. Epub 2015 Jul 18.

PMID:
26198421
17.

Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer.

Seymour ZA, Chang AJ, Zhang L, Kirby N, Descovich M, Roach M 3rd, Hsu IC, Gottschalk AR.

Pract Radiat Oncol. 2015 Sep-Oct;5(5):e465-e472. doi: 10.1016/j.prro.2015.02.001. Epub 2015 Mar 18.

PMID:
25795252
18.

Comparison between target margins derived from 4DCT scans and real-time tumor motion tracking: insights from lung tumor patients treated with robotic radiosurgery.

Descovich M, McGuinness C, Kannarunimit D, Chen J, Pinnaduwage D, Pouliot J, Kased N, Gottschalk AR, Yom SS.

Med Phys. 2015 Mar;42(3):1280-7. doi: 10.1118/1.4907956.

PMID:
25735283
19.

ACR appropriateness Criteria® Postradical prostatectomy irradiation in prostate cancer.

Gustafson GS, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Hsu IC, Lloyd S, Mclaughlin PW, Merrick GS, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ.

Oncology (Williston Park). 2014 Dec;28(12):1125-30, 1132-6.

20.

ACR Appropriateness Criteria® Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer.

Nguyen PL, Aizer A, Assimos DG, D'Amico AV, Frank SJ, Gottschalk AR, Gustafson GS, Hsu IC, McLaughlin PW, Merrick G, Rosenthal SA, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ; American College of Radiology, Expert Panel on Radiation OncologyProstate.

Am J Clin Oncol. 2014 Jun;37(3):278-88. doi: 10.1097/COC.0000000000000049. Review.

PMID:
25180754
21.

Pre-plan parameters predict post-implant D90 ≥ 140 Gy for (125)I permanent prostate implants.

Alexander J, Weinberg V, Gottschalk AR, Hsu IC, Shinohara K, Roach M 3rd.

J Contemp Brachytherapy. 2014 Jun;6(2):143-53. doi: 10.5114/jcb.2014.43248. Epub 2014 Jun 3.

22.

Response to Drs Rogers, Hayes, and Demanes.

Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G; Expert Panel on Radiation Oncology–Prostate.

Brachytherapy. 2014 Sep-Oct;13(5):523-5. doi: 10.1016/j.brachy.2014.05.007. Epub 2014 May 28. No abstract available.

PMID:
24880587
23.

Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes.

Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M 3rd, Carroll PR.

PLoS One. 2014 Mar 3;9(3):e89754. doi: 10.1371/journal.pone.0089754. eCollection 2014. Erratum in: PLoS One. 2016 Oct 6;11(10 ):e0164558.

24.

Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery.

Crehange G, Izaguirre A, Weinberg V, Hsu CC, Gottschalk AR, Hsu IC, Shinohara K, Carroll P, Roach M 3rd.

Am J Clin Oncol. 2016 Apr;39(2):167-72. doi: 10.1097/COC.0000000000000032.

PMID:
24441584
25.

Evaluation of ray tracing and Monte Carlo algorithms in dose calculation and clinical outcomes for robotic stereotactic body radiotherapy of lung cancers.

Braunstein SE, Dionisio SA, Lometti MW, Pinnaduwage DS, Chuang CF, Yom SS, Gottschalk AR, Descovich M.

J Radiosurg SBRT. 2014;3(1):67-79.

26.

ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer.

Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G.

Brachytherapy. 2014 Jan-Feb;13(1):27-31. doi: 10.1016/j.brachy.2013.11.007. Epub 2013 Dec 22. Review.

PMID:
24368283
27.

Analysis of dose distribution and risk of pneumonitis in stereotactic body radiation therapy for centrally located lung tumors: a comparison of robotic radiosurgery, helical tomotherapy and volumetric modulated arc therapy.

Kannarunimit D, Descovich M, Garcia A, Chen J, Weinberg V, Mcguinness C, Pinnaduwage D, Murnane J, Gottschalk AR, Yom SS.

Technol Cancer Res Treat. 2015 Feb;14(1):49-60. doi: 10.7785/tcrt.2012.500394. Epub 2014 Nov 11.

PMID:
24325136
28.

Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: implications for focal salvage brachytherapy.

Crehange G, Krishnamurthy D, Cunha JA, Pickett B, Kurhanewicz J, Hsu IC, Gottschalk AR, Shinohara K, Roach M 3rd, Pouliot J.

Radiother Oncol. 2013 Nov;109(2):246-50. doi: 10.1016/j.radonc.2013.10.028. Epub 2013 Nov 11.

29.

Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife.

Descovich M, Carrara M, Morlino S, Pinnaduwage DS, Saltiel D, Pouliot J, Nash MB, Pignoli E, Valdagni R, Roach M 3rd, Gottschalk AR.

J Appl Clin Med Phys. 2013 Sep 6;14(5):162-72. doi: 10.1120/jacmp.v14i5.4333.

30.

ACR Appropriateness Criteria prostate cancer--pretreatment detection, staging, and surveillance.

Eberhardt SC, Carter S, Casalino DD, Merrick G, Frank SJ, Gottschalk AR, Leyendecker JR, Nguyen PL, Oto A, Porter C, Remer EM, Rosenthal SA.

J Am Coll Radiol. 2013 Feb;10(2):83-92. doi: 10.1016/j.jacr.2012.10.021.

PMID:
23374687
31.

Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer.

Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M 3rd.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):370-7. doi: 10.1016/j.ijrobp.2012.04.028. Epub 2012 Jun 4.

PMID:
22672747
32.

Temporal compartmental dosing effects for robotic prostate stereotactic body radiotherapy.

Shiao SL, Sahgal A, Hu W, Jabbari S, Chuang C, Descovich M, Hsu IC, Gottschalk AR, Roach M 3rd, Ma L.

Phys Med Biol. 2011 Dec 21;56(24):7767-75. doi: 10.1088/0031-9155/56/24/006. Epub 2011 Nov 22.

PMID:
22107791
33.

Patellar metastatic melanoma in a 13-year-old boy.

Burk TF, Horvai AE, Gottschalk AR, Leong SP, Kashani-Sabet M, Goldsby RE, Law J, O'Donnell RJ.

Am J Orthop (Belle Mead NJ). 2010 Dec;39(12):582-6. Review.

PMID:
21720575
34.

Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.

Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M 3rd, Gottschalk AR.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):228-34. doi: 10.1016/j.ijrobp.2010.10.026. Epub 2010 Dec 22.

PMID:
21183287
35.

High-dose-rate brachytherapy boost for prostate cancer: comparison of two different fractionation schemes.

Kaprealian T, Weinberg V, Speight JL, Gottschalk AR, Roach M 3rd, Shinohara K, Hsu IC.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):222-7. doi: 10.1016/j.ijrobp.2010.09.021. Epub 2010 Dec 14.

PMID:
21163586
36.

Comparison of patient megavoltage cone beam CT images acquired with an unflattened beam from a carbon target and a flattened treatment beam.

Faddegon BA, Aubin M, Bani-Hashemi A, Gangadharan B, Gottschalk AR, Morin O, Sawkey D, Wu V, Yom SS.

Med Phys. 2010 Apr;37(4):1737-41.

PMID:
20443494
37.

A diamond target for megavoltage cone-beam CT.

Sawkey D, Lu M, Morin O, Aubin M, Yom SS, Gottschalk AR, Bani-Hashemi A, Faddegon BA.

Med Phys. 2010 Mar;37(3):1246-53.

PMID:
20384262
38.

Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer.

Hossain S, Xia P, Huang K, Descovich M, Chuang C, Gottschalk AR, Roach M 3rd, Ma L.

Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):58-63. doi: 10.1016/j.ijrobp.2009.07.1752. Epub 2010 Feb 3.

PMID:
20133073
39.

High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience.

Jabbari S, Hsu IC, Kawakami J, Weinberg VK, Speight JL, Gottschalk AR, Roach M 3rd, Shinohara K.

Brachytherapy. 2009 Oct-Dec;8(4):339-44. doi: 10.1016/j.brachy.2009.02.004. Epub 2009 May 9.

PMID:
19428310
40.

Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.

Jabbari S, Weinberg VK, Shinohara K, Speight JL, Gottschalk AR, Hsu IC, Pickett B, McLaughlin PW, Sandler HM, Roach M 3rd.

Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):36-42. doi: 10.1016/j.ijrobp.2009.01.029.

PMID:
19409729
41.

Dose recalculation and the Dose-Guided Radiation Therapy (DGRT) process using megavoltage cone-beam CT.

Cheung J, Aubry JF, Yom SS, Gottschalk AR, Celi JC, Pouliot J.

Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):583-92. doi: 10.1016/j.ijrobp.2008.12.034. Epub 2009 Apr 3.

PMID:
19345518
42.

Simulated real time image guided intrafraction tracking-delivery for hypofractionated prostate IMRT.

Hossain S, Xia P, Chuang C, Verhey L, Gottschalk AR, Mu G, Ma L.

Med Phys. 2008 Sep;35(9):4041-8.

PMID:
18841856
43.

Proposed rectal dose constraints for patients undergoing definitive whole pelvic radiotherapy for clinically localized prostate cancer.

Chan LW, Xia P, Gottschalk AR, Akazawa M, Scala M, Pickett B, Hsu IC, Speight J, Roach M 3rd.

Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):69-77. doi: 10.1016/j.ijrobp.2007.12.045. Epub 2008 Mar 14. Review.

PMID:
18342454
44.

Patient dose considerations for routine megavoltage cone-beam CT imaging.

Morin O, Gillis A, Descovich M, Chen J, Aubin M, Aubry JF, Chen H, Gottschalk AR, Xia P, Pouliot J.

Med Phys. 2007 May;34(5):1819-27.

PMID:
17555263
45.

Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy.

Schiffner DC, Gottschalk AR, Lometti M, Aubin M, Pouliot J, Speight J, Hsu IC, Shinohara K, Roach M 3rd.

Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):610-9.

PMID:
17236978
46.

Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience.

Lee B, Shinohara K, Weinberg V, Gottschalk AR, Pouliot J, Roach M 3rd, Hsu IC.

Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1106-12. Epub 2006 Dec 29.

PMID:
17197119
47.

Clinical outcomes of intraoperative radiation therapy for extremity sarcomas.

Tran QN, Kim AC, Gottschalk AR, Wara WM, Phillips TL, O'donnell RJ, Weinberg V, Haas-Kogan DA.

Sarcoma. 2006;2006(1):91671.

48.

Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism.

Gottschalk AR, Doan A, Nakamura JL, Stokoe D, Haas-Kogan DA.

Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1221-7.

PMID:
16253776
49.

Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer.

Hsu IC, Cabrera AR, Weinberg V, Speight J, Gottschalk AR, Roach M 3rd, Shinohara K.

Brachytherapy. 2005;4(3):202-6.

PMID:
16182220
50.

Management of isolated renal fossa recurrence following radical nephrectomy.

Master VA, Gottschalk AR, Kane C, Carroll PR.

J Urol. 2005 Aug;174(2):473-7; discussion 477.

PMID:
16006867

Supplemental Content

Loading ...
Support Center